ArticleTherapeutic advances in medical oncology2024

SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors.

Pascal Hammel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.